Amgen (AMGN) : Nomura Asset Management Co Ltd scooped up 9,246 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 302,635 shares of Amgen which is valued at $52,361,908.Amgen makes up approximately 0.94% of Nomura Asset Management Co Ltd’s portfolio.
Other Hedge Funds, Including , Proshare Advisors reduced its stake in AMGN by selling 3,873 shares or 0.73% in the most recent quarter. The Hedge Fund company now holds 527,882 shares of AMGN which is valued at $91,334,144. Amgen makes up approx 1.12% of Proshare Advisors’s portfolio.Pinnacle Wealth Management Advisory Group boosted its stake in AMGN in the latest quarter, The investment management firm added 125 additional shares and now holds a total of 3,315 shares of Amgen which is valued at $575,683. Amgen makes up approx 0.45% of Pinnacle Wealth Management Advisory Group’s portfolio.Rand Wealth boosted its stake in AMGN in the latest quarter, The investment management firm added 110 additional shares and now holds a total of 1,696 shares of Amgen which is valued at $294,527. Amgen makes up approx 0.04% of Rand Wealth’s portfolio. Greatmark Investment Partners added AMGN to its portfolio by purchasing 1,320 company shares during the most recent quarter which is valued at $227,080. Amgen makes up approx 0.10% of Greatmark Investment Partners’s portfolio.Telemus Capital boosted its stake in AMGN in the latest quarter, The investment management firm added 361 additional shares and now holds a total of 19,814 shares of Amgen which is valued at $3,234,636. Amgen makes up approx 0.37% of Telemus Capital’s portfolio.
Amgen closed down -0.46 points or -0.27% at $171.51 with 25,12,225 shares getting traded on Monday. Post opening the session at $172.37, the shares hit an intraday low of $171.1201 and an intraday high of $172.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.